SHTDY (Sinopharm Group Co) Institutional Ownership: 0.00% (As of Jul. 09, 2026)


SHTDY Sinopharm Group Co Ltd SHTDY
73 GF Score
Price $10.88
GF Value $13.28
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sinopharm Group Co Institutional Ownership?

Sinopharm Group Co SHTDY +0.18% 73 Institutional Ownership is 0.00% as of Jul. 09, 2026. GuruFocus rates SHTDY with a GF Score™ of 73/100 and a GF Value™ of $13.28 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sinopharm Group Co's institutional ownership is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sinopharm Group Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sinopharm Group Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Sinopharm Group Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Sinopharm Group Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sinopharm Group Co Institutional Ownership Chart

Sinopharm Group Co Historical Data

The historical data trend for Sinopharm Group Co can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 0.38 0.02 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.02
SHTDY
73GF Score
Sinopharm Group Co Ltd SHTDY
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sinopharm Group Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.00% mean?
Sinopharm Group Co (SHTDY) has a Institutional Ownership of 0.00% as of Jul. 09, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sinopharm Group Co and its competitors.
Is Sinopharm Group Co's Institutional Ownership too high?
Sinopharm Group Co's current Institutional Ownership is 0.00%. Overall, Sinopharm Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Institutional Ownership compare to MCK and CAH?
Sinopharm Group Co's Institutional Ownership of 0.00% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Distribution company?
A good Institutional Ownership depends on the Medical Distribution industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Sinopharm Group Co and its competitors. Sinopharm Group Co's current Institutional Ownership is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDY) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.28, compared to a current price of $10.88 — trading 18.1% below its estimated fair value. The current Institutional Ownership is 0.00%. Sinopharm Group Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Sinopharm Group Co (SHTDY), the current Institutional Ownership is 0.00% as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sinopharm Group Co (SHTDY) Overvalued in 2026?

Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued. The current stock price of $10.88 is trading 18.1% below its estimated GF Value™ of $13.28. GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.

Key valuation signals for SHTDY:

  • Institutional Ownership: 0.00%
  • GF Value™: $13.28 vs. price of $10.88 (18.1% below fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the SHTDY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sinopharm Group Co Business Description

Address No. 385, East Longhua Road, Sinopharm Group Building, Huangpu District, Shanghai, CHN, 200023
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
73GF Score

Get the complete analysis for SHTDY

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.88
Price
$13.28
GF Value